RUTHERFORD, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the third quarter on Thursday, November 10, 2016. The company and key management team members will also hold a live investor conference call and webcast at 8:30 AM Eastern on Thursday, November 10, 2016 to discuss the financial results, and provide company updates. Conference Call & WebcastThursday, November 10, 8:30 AM Eastern Time Domestic: 877-723-9502International: 719-325-4747Conference ID: 3129820Webcast: http://public.viavid.com/index.php?id=121874 Replays - Available through November 24, 2016Domestic: 844-512-2921International: 412-317-6671Conference ID: 3129820 ABOUT CANCER GENETICS Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. For more information, please visit or follow CGI at: Internet: www.cancergenetics.com Twitter: @Cancer_Genetics Facebook: www.facebook.com/CancerGenetics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.'s expectations regarding future financial and/or operating results and potential for our tests and services, and future revenues or growth in this press release constitute forward-looking statements.